Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001765581-20-000055
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-27 18:36:05
Reporting Period:
2020-05-26
Accepted Time:
2020-05-27 18:36:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1232524 Jazz Pharmaceuticals Plc JAZZ Pharmaceutical Preparations (2834) 981032470
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1536639 Seamus Mulligan 5Th Fl, Waterloo Exchange
Waterloo Rd
Dublin 4 L2
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2020-05-26 15,000 $110.65 1,117,788 No 4 P Direct
Ordinary Shares Acquisiton 2020-05-27 5,243 $109.55 1,123,031 No 4 P Direct
Ordinary Shares Acquisiton 2020-05-27 8,391 $110.52 1,131,422 No 4 P Direct
Ordinary Shares Acquisiton 2020-05-27 9,884 $111.56 1,141,306 No 4 P Direct
Ordinary Shares Acquisiton 2020-05-27 11,482 $112.32 1,152,788 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $110.1800 to $110.9800. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
  2. Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $109.0300 to $110.0200. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
  3. Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from 110.0300 to $111.0100. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
  4. Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $111.0350 to $112.0200. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
  5. Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $112.0500 to $112.6600. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.